natgillin/translations-raw huggingface dataset:
5-amino-3-phenyl-1,2,4-triazol-1-yl-N, N,N',N'-tetramethylphosphonic diamide
5-amino-3-phenyl-1,2,4-triazol-1-yl-N,N,N',N'-tetramethylphosphonic diamide
O, O,O, O-tetraethyl dithiopyrophosphate
O,O,O,O-tetraethyl dithiopyrophosphate
O, O-diethyl-O-2-ethylthioethyl phosphorothioate
O,O-diethyl-O-2-ethylthioethyl phosphorothioate
O-2-ethylthioethyl O, O-dimethyl phosphorothioate
O-2-ethylthioethyl O,O-dimethyl phosphorothioate
O, O-diethyl isopropylcarbamoylmethyl phosphorodithioate
O,O-diethyl isopropylcarbamoylmethyl phosphorodithioate
O, O-diethyl ethylthiomethyl phosphorodithioate
O,O-diethyl ethylthiomethyl phosphorodithioate
O, O-diethyl O-4-nitrophenyl phosphorothioate
O,O-diethyl O-4-nitrophenyl phosphorothioate
O, O-dimethyl O-4-nitrophenyl phosphorothioate
O,O-dimethyl O-4-nitrophenyl phosphorothioate
S-(2,5-dichlorophenylthiomethyl) O, O-diethyl phosphorodithioate
S-(2,5-dichlorophenylthiomethyl) O,O-diethyl phosphorodithioate
O-3-chloro-4-methylcoumarin-7-yl O, O-diethyl phosphorothioate
O-3-chloro-4-methylcoumarin-7-yl O,O-diethyl phosphorothioate
O, O-dimethyl-4-oxobenzotriazin-3-ylmethyl phosphorodithioate
O,O-dimethyl-4-oxobenzotriazin-3-ylmethyl phosphorodithioate
O, O-diethyl O-2-isopropyl-6-methylpyrimidin-4-yl phosphorothioate
O,O-diethyl O-2-isopropyl-6-methylpyrimidin-4-yl phosphorothioate
1,2-bis (ethoxycarbonyl) ethyl O, O-dimethyl phosphorodithioate
1,2-bis (ethoxycarbonyl) ethyl O,O-dimethyl phosphorodithioate
O-(3-chloro-4-nitrophenyl) O, O-dimethyl phosphorothioate
O-(3-chloro-4-nitrophenyl) O,O-dimethyl phosphorothioate
O-4-chloro-3-nitrophenyl O, O-dimethyl phosphorothioate
O-4-chloro-3-nitrophenyl O,O-dimethyl phosphorothioate
4-chlorophenylthiomethyl O, O-diethyl phosphorodithioate
4-chlorophenylthiomethyl O,O-diethyl phosphorodithioate
N-ethoxycarbonyl-N-methylcarbamoylmethyl O, O-diethyl phosphorodithioate
N-ethoxycarbonyl-N-methylcarbamoylmethyl O,O-diethyl phosphorodithioate
S-2-(ethylsulphinyl)ethyl O, O-dimethyl phosphorothioate
S-2-(ethylsulphinyl)ethyl O,O-dimethyl phosphorothioate
O, O,O',O'-tetraethyl S, S'-methylenedi (phosphorodithioate);
O,O,O',O'-tetraethyl S,S'-methylenedi (phosphorodithioate);
O, O-dimethyl-O-(4-methylthion-m-tolyl) phosphorothioate
O,O-dimethyl-O-(4-methylthion-m-tolyl) phosphorothioate
S-2-ethylthioethyl O, O-dimethyl phosphorodithioate
S-2-ethylthioethyl O,O-dimethyl phosphorodithioate
O, O-dimethyl methylcarbamoylmethyl phosphorodithioate
O,O-dimethyl methylcarbamoylmethyl phosphorodithioate
O, O-dimethyl O-4-nitro-m-tolyl phosphorothioate
O,O-dimethyl O-4-nitro-m-tolyl phosphorothioate
O, O-diethyl 4-oxobenzotriazin-3-ylmethyl phosphorodithioate
O,O-diethyl 4-oxobenzotriazin-3-ylmethyl phosphorodithioate
N-formyl-N-methylcarbamoylmethyl O, O-dimethyl phosphorodithioate
N-formyl-N-methylcarbamoylmethyl O,O-dimethyl phosphorodithioate
O, O-dimethyl-S-(morpholinocarbonylmethyl) phosphorodithioate
O,O-dimethyl-S-(morpholinocarbonylmethyl) phosphorodithioate
O, O-dimethyl S-2-(1-methylcarbamoylethylthio) ethyl phosphorothioate
O,O-dimethyl S-2-(1-methylcarbamoylethylthio) ethyl phosphorothioate
O, O-diethyl 2-ethylthioethyl phosphorodithioate
O,O-diethyl 2-ethylthioethyl phosphorodithioate
N, N'- di-isopropylphosphorodiamidic fluoride
N,N'- di-isopropylphosphorodiamidic fluoride
1,4-dioxan-2,3-diyl-O, O,O',O'-tetraethyl di(phosphorodithioate)
1,4-dioxan-2,3-diyl-O,O,O',O'-tetraethyl di(phosphorodithioate)
O-4-bromo-2,5-dichlorophenyl O, O-diethyl phosphorothioate
O-4-bromo-2,5-dichlorophenyl O,O-diethyl phosphorothioate
S-[2-(ethylsulphinyl)ethyl] O, O-dimethyl phosphorodithioate
S-[2-(ethylsulphinyl)ethyl] O,O-dimethyl phosphorodithioate
O, O-dimethyl S-methylcarbamoylmethyl phosphorothioate
O,O-dimethyl S-methylcarbamoylmethyl phosphorothioate
S-(6-chloro-2-oxobenzoxazolin-3-ylmethyl) O, O-diethyl phosphorodithioate
S-(6-chloro-2-oxobenzoxazolin-3-ylmethyl) O,O-diethyl phosphorodithioate
2,3-dihydro-5-methoxy-2-oxo-1,3,4-thiadiazol-3-ylmethyl-O, O-dimethylphosphorodithioate
2,3-dihydro-5-methoxy-2-oxo-1,3,4-thiadiazol-3-ylmethyl-O,O-dimethylphosphorodithioate
S-(N-(1-cyano-1-methylethyl)carbamoylmethyl) O, O-diethyl phosphorothioate
S-(N-(1-cyano-1-methylethyl)carbamoylmethyl) O,O-diethyl phosphorothioate
S-[2-(isopropylsulphinyl)ethyl] O, O-dimethyl phosphorothioate
S-[2-(isopropylsulphinyl)ethyl] O,O-dimethyl phosphorothioate
O, S-dimethyl acetylphosphoramidothioate
O,S-dimethyl acetylphosphoramidothioate
2-methoxyethylcarbamoylmethyl O, O-dimethyl phosphorodithioate
2-methoxyethylcarbamoylmethyl O,O-dimethyl phosphorodithioate
O, O,O',O'-tetrapropyl dithiopyrophosphate
O,O,O',O'-tetrapropyl dithiopyrophosphate
O-4-(4-chlorophenylazo)phenyl O, O-dimethyl phosphorothioate
O-4-(4-chlorophenylazo)phenyl O,O-dimethyl phosphorothioate
O, O-diisopropyl 2-phenylsulphonylaminoethyl phosphorodithioate
O,O-diisopropyl 2-phenylsulphonylaminoethyl phosphorodithioate
O-4-cyanophenyl O, O-dimethyl phosphorothioate
O-4-cyanophenyl O,O-dimethyl phosphorothioate
2-chloro-1-phthalimidoethyl O, O-diethyl phosphorodithioate
2-chloro-1-phthalimidoethyl O,O-diethyl phosphorodithioate
ethylcarbamoylmethyl O, O-dimethyl phosphorodithioate
ethylcarbamoylmethyl O,O-dimethyl phosphorodithioate
O, O-diethyl O-4-methylsulfinylphenyl phosphorothioate
O,O-diethyl O-4-methylsulfinylphenyl phosphorothioate
O, O-bis(4-chlorophenyl) N-acetimidoylphosphoramidothioate
O,O-bis(4-chlorophenyl) N-acetimidoylphosphoramidothioate
O, S-dimethyl phosphoramidothioate
O,S-dimethyl phosphoramidothioate
O, O-diethyl O-2-diethylamino-6-methylpyrimidin-4-yl phosphorothioate
O,O-diethyl O-2-diethylamino-6-methylpyrimidin-4-yl phosphorothioate
O, O-dimethyl phthalimidomethyl S-phosphorodithioate
O,O-dimethyl phthalimidomethyl S-phosphorodithioate
ethyl-S, S-dipropyl phosphorodithioate
ethyl-S,S-dipropyl phosphorodithioate
O-4-bromo-2,5-dichlorophenyl O, O-dimethyl phosphorothioate
O-4-bromo-2,5-dichlorophenyl O,O-dimethyl phosphorothioate
O, O-diethyl O-pyrazin-2-yl phosphorothioate;
O,O-diethyl O-pyrazin-2-yl phosphorothioate;
S-chloromethyl O, O-diethyl phosphorodithioate
S-chloromethyl O,O-diethyl phosphorodithioate
O, O-dimethyl O-2-methylthioethyl phosphorothioate
O,O-dimethyl O-2-methylthioethyl phosphorothioate
O, O-dimethyl S-2-methylthioethyl phosphorothioate
O,O-dimethyl S-2-methylthioethyl phosphorothioate
O, O-diethyl phthalimidophosphonothioate
O,O-diethyl phthalimidophosphonothioate
O-ethyl S, S-diphenyl phosphorodithioate
O-ethyl S,S-diphenyl phosphorodithioate
O-6-ethoxy-2-ethylpyrimidin-4-yl O, O-dimethylphosphorothioate
O-6-ethoxy-2-ethylpyrimidin-4-yl O,O-dimethylphosphorothioate
N, N-bis(phosphonomethyl)glycine
N,N-bis(phosphonomethyl)glycine
S-ethylsulphinylmethyl O, O-diisopropylphosphorodithioate
S-ethylsulphinylmethyl O,O-diisopropylphosphorodithioate
S-2-isopropylthioethyl O, O-dimethyl phosphorodithioate;
S-2-isopropylthioethyl O,O-dimethyl phosphorodithioate;
O, O-diethyl O-5-phenylisoxazol-3-ylphosphorothioate
O,O-diethyl O-5-phenylisoxazol-3-ylphosphorothioate
S-(chlorophenylthiomethyl) O, O-dimethylphosphorodithioate;
S-(chlorophenylthiomethyl) O,O-dimethylphosphorodithioate;
S-2-methylpiperidinocarbonylmethyl-O, O-dipropyl phosphorodithioate
S-2-methylpiperidinocarbonylmethyl-O,O-dipropyl phosphorodithioate
O-(2-diethylamino-6-methylpyrimidin-4-yl) O, O-dimethyl phosphorothioate
O-(2-diethylamino-6-methylpyrimidin-4-yl) O,O-dimethyl phosphorothioate
O, O-diethyl O-(6-ethoxycarbonyl-5-methylpyrazolo[2,3-a]pyrimidin-2-yl) phosphorothioate
O,O-diethyl O-(6-ethoxycarbonyl-5-methylpyrazolo[2,3-a]pyrimidin-2-yl) phosphorothioate
O, O-diethyl-O-quinoxalin-2-yl phosphorothioate
O,O-diethyl-O-quinoxalin-2-yl phosphorothioate
O, O-diethyl-O-1-phenyl-1H,2,4-triazol-3-yl phosphorothioate
O,O-diethyl-O-1-phenyl-1H,2,4-triazol-3-yl phosphorothioate
ethylenediammonium O, O-bis(octyl) phosphorodithioate, mixed isomers
ethylenediammonium O,O-bis(octyl) phosphorodithioate, mixed isomers
reaction mass of copper(I) O, O-diisopropyl phosphorodithioate and copper(I) O-isopropyl O-(4-methylpent-2-yl) phosphorodithioate and copper(I) O, O-bis(4-methylpent-2-yl) phosphorodithioate
reaction mass of copper(I) O,O-diisopropyl phosphorodithioate and copper(I) O-isopropyl O-(4-methylpent-2-yl) phosphorodithioate and copper(I) O,O-bis(4-methylpent-2-yl) phosphorodithioate
O-(5-chloro-1-isopropyl-1,2,4-triazol-3-yl) O, O-diethyl phosphorothioate
O-(5-chloro-1-isopropyl-1,2,4-triazol-3-yl) O,O-diethyl phosphorothioate
calcium P, P'-(1-hydroxyethylene)bis(hydrogen phosphonate)dihydrate
calcium P,P'-(1-hydroxyethylene)bis(hydrogen phosphonate)dihydrate
reaction mass of: thiobis(4,1-phenylene)-S, S,S',S'-tetraphenyldisulfonium bishexafluorophosphate;
reaction mass of: thiobis(4,1-phenylene)-S,S,S',S'-tetraphenyldisulfonium bishexafluorophosphate;
reaction mass of: di-(1-octane-N, N,N-trimethylammonium) octylphosphate;
reaction mass of: di-(1-octane-N,N,N-trimethylammonium) octylphosphate;
1-octane-N, N,N-trimethylammonium di-octylphosphate;
1-octane-N,N,N-trimethylammonium di-octylphosphate;
1-octane-N, N,N-trimethylammonium octylphosphate
1-octane-N,N,N-trimethylammonium octylphosphate
O, O,O-tris(2(or 4)-C9-10-isoalkylphenyl) phosphorothioate
O,O,O-tris(2(or 4)-C9-10-isoalkylphenyl) phosphorothioate
1-chloro-N, N-diethyl-1,1-diphenyl-1-(phenylmethyl)phosphoramine
1-chloro-N,N-diethyl-1,1-diphenyl-1-(phenylmethyl)phosphoramine
P, P,P',P'-tetrakis-(o-methoxyphenyl)propane-1,3-diphosphine
P,P,P',P'-tetrakis-(o-methoxyphenyl)propane-1,3-diphosphine
Carc.
1B; H350: C ≥ 0,01 % Muta.
dimexano(ISO); bis(methoxythiocarbonyl) disulphide
bis(methoxythiocarbonyl) disulphide
1B; H314: C ≥ 25 %
Skin Irrit. 2; H315: 10 % ≤ C < 25 % Eye Irrit.
Eye Irrit.
p-toluenesulphonic acid (containing a maximum of 5 % H2SO4)
10 % ≤ C < 25 %
203-180-0 104-15-4 Eye Irrit.
p-toluenesulphonic acid (containing a maximum of 5 % H2SO4)
STOT SE 3 Skin Irrit.
1,3-propanesultone;
1,2-oxathiolane 2,2-dioxide
dilithium 6-acetamido-4-hydroxy-3-(4-((2-sulphonatooxy)ethylsulphonyl)phenylazo)naphthalene-2-sulphonate
disodium S,S-hexane-1,6-diyldi(thiosulphate) dihydrate
GHS07
Wng
N, N,N',N'-tetramethyldithiobis(ethylene)diamine dihydrochloride
N,N,N',N'-tetramethyldithiobis(ethylene)diamine dihydrochloride
1,3-bis(phenylsulfonylthio)-2-(N, N-dimethylamino)propane
1,3-bis(phenylsulfonylthio)-2-(N,N-dimethylamino)propane
sodium hydrogensulphite... %;
sodium hydrogensulphite . . . %;
sodium bisulphite... %
sodium bisulphite . . . %
4-methyl-N, N-bis(2-(((4-methylphenyl)sulfonyl)amino)ethyl)benzenesulfonamide
4-methyl-N,N-bis(2-(((4-methylphenyl)sulfonyl)amino)ethyl)benzenesulfonamide
N, N-bis(2-(p-toluenesulfonyloxy)ethyl)-p-toluenesulfonamide
N,N-bis(2-(p-toluenesulfonyloxy)ethyl)-p-toluenesulfonamide
(Z)-13-docosenyl-N, N-bis(2-hydroxyethyl)-N-methyl-ammonium-chloride
(Z)-13-docosenyl-N,N-bis(2-hydroxyethyl)-N-methyl-ammonium-chloride
N, N,N-trimethyl-2,3-bis(stearoyloxy)propylammonium chloride
N,N,N-trimethyl-2,3-bis(stearoyloxy)propylammonium chloride
Resp.
Resp. Sens.; H334: C ≥ 0,2 %
Sens.; H334: C ≥ 0,2 %
Skin Sens.; H317: C ≥ 0,2 % G 3
024-004-00-7 sodium dichromate anhydrate
sodium dichromate anhydrate
Sens.; H334: C ≥ 0,2 % Skin Sens.; H317: C ≥ 0,2 %
Skin Sens.; H317: C ≥ 0,2 %
Sens.; H334: C ≥ 0,2 %
Skin Sens.; H317: C ≥ 0,2 % 3
024-005-00-2 chromyl dichloride;
chromyl dichloride;
1B; H314: 5 % ≤ C < 10 %
1B; H314: 5 % ≤ C < 10 % Skin Irrit.
Skin Irrit.
0,5 % ≤ C < 5 % Eye Irrit.
2; H319: 0,5 % ≤ C < 5 %
STOT SE 3; H335: 0,5 % ≤ C < 5 % Skin Sens.
024-006-00-8 potassium chromate
potassium chromate
Skin Sens.
zinc chromates including zinc potassium chromate — — Carc. 1A Acute Tox. 4 * Skin Sens. 1
C ≥ 0.5 %
Aquatic Acute 1 Aquatic Chronic 1 H350 H302 H317 H400 H410 GHS08 GHS07 GHS09 Dgr H350 H302 H317
Aquatic Acute 1 Aquatic Chronic 1 H350 H302 H317 H400 H410 GHS08 GHS07 GHS09 Dgr H350 H302 H317 H410 A 024-008-00-9 calcium chromate
calcium chromate
Skin Sens.; H317: C ≥ 0,2 %
024-019-00-9 Main component: acetoacetic acid anilide/3-amino-1-hydroxybenzene (ATAN-MAP): trisodium 6-[(2 or 3 or 4)-amino-(4 or 5 or 6)-hydroxyphenylazo]-5'-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato-6''-[1-(phenylcarbamoyl)ethylazo]-5'''-(phenylsulfamoyl)-3''-sulfonatonaphthalene-2''-azobenzene-1'',2'''-diolatochromate (III);
by-product 1: acetoacetic acid anilide/acetoacetic acid anilide (ATAN-ATAN): trisodium bis6-[1-(phenylcarbamoyl)ethylazo]-5'-(phenylsulfonyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolatochromate (III); by-product 2: 3-amino-1-hydroxybenzene/3-amino-1-hydroxybenzene (MAP-MAP): trisodium bis6-[(2 or 3 or 4)-amino-(4 or 5 or 6)-hydroxyphenylazo]-5'-(phenylsulfamoyl)-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato chromate (III) 419-230-1 — Skin Sens. 1 Aquatic Chronic 3 H317 H412 GHS07 Wng H317 H412 024-020-00-4 trisodium bis[(3'-nitro-5'-sulfonato(6-amino-2-[4-(2-hydroxy-1-naphtylazo)phenylsulfonylamino]pyrimidin-5-azo)benzene-2',4-diolato)]chromate(III)
trisodium bis[(3'-nitro-5'-sulfonato(6-amino-2-[4-(2-hydroxy-1-naphtylazo)phenylsulfonylamino]pyrimidin-5-azo)benzene-2',4-diolato)]chromate(III)
bis(N, N',N''-trimethyl-1,4,7-triazacyclononane)-trioxo-dimanganese (IV) di(hexafluorophosphate) monohydrate
bis(N,N',N''-trimethyl-1,4,7-triazacyclononane)-trioxo-dimanganese (IV) di(hexafluorophosphate) monohydrate
reaction mass of: tri-sodium [29H, 31H-phthalocyanine-C, C,C-trisulfonato (6-)-N29,N30,N31,N32] manganate (3-);
reaction mass of: tri-sodium [29H, 31H-phthalocyanine-C,C,C-trisulfonato (6-)-N29,N30,N31,N32] manganate (3-);
tetrasodium [29H,31H-phthalocyanine-C, C,C, C-tetrasulfonato (6-)-N29,N30,N31,N32], manganate (3-);
tetrasodium [29H,31H-phthalocyanine-C,C,C,C-tetrasulfonato (6-)-N29,N30,N31,N32], manganate (3-);
pentasodium [29H,31H-phthalocyanine-C, C,C, C,C-pentasulfonato (6-)-N29,N30,N31,N32] manganate (3-)
pentasodium [29H,31H-phthalocyanine-C,C,C,C,C-pentasulfonato (6-)-N29,N30,N31,N32] manganate (3-)
Carc.
1B; H350i: C ≥ 0,01 % 1
028-001-00-1 tetracarbonylnickel;
tetracarbonylnickel;
(tris(chloromethyl)phthalocyaninato)copper(II), reaction products with N-methylpiperazine and methoxyacetic acid
tris(octadec-9-enylammonium) (trisulfonatophthalocyaninato)copper(II) 403-210-4 — Eye Dam.
trimethyltin compounds, with the exception of those specified elsewhere in this Annex
050-006-00-2 triethyltin compounds, with the exception of those specified elsewhere in this Annex
triethyltin compounds, with the exception of those specified elsewhere in this Annex
tripropyltin compounds, with the exception of those specified elsewhere in this Annex
tripropyltin compounds, with the exception of those specified elsewhere in this Annex — —
tributyltin compounds, with the exception of those specified elsewhere in this Annex
050-012-00-5 tetracyclohexylstannane; [1]
tetracyclohexylstannane; [1]
2; H315: 0,02 % ≤ C < 0,2 %
0,02 % ≤ C < 0,2 % Eye Irrit.
Eye Irrit.
0,02 % ≤ C < 0,2 %
2; H319: 0,02 % ≤ C < 0,2 % STOT SE 3; H335: C ≥ 0,02 %
STOT SE 3; H335: C ≥ 0,02 %
Acute Tox.
STOT SE 3 Skin Irrit. 2
Eye Irrit.
Aquatic Chronic 1 H302 H319 H335 H315 H400 H410 GHS07 GHS09 Wng H302 H319 H335 H315 H410
STOT SE 3 Skin Irrit.
organic compounds of mercury with the exception of those specified elsewhere in this Annex —
Aquatic Acute 1
STOT RE 2; H373: C ≥ 0,1 % A
080-005-00-2 mercury difulminate;
mercury difulminate;
Repr.
2; H361f: C ≥ 2,5 % *
2; H361f: C ≥ 2,5 %
STOT RE 2; H373: C ≥ 0,5 % A
STOT RE 2; H373: C ≥ 0,5 %
082-002-00-1 lead alkyls — —
Repr.
1A; H360D: C ≥ 0,1 % *
1A; H360D: C ≥ 0,1 %
STOT RE 2; H373: C ≥ 0,05 % A
082-003-00-7 lead diazide;
lead diazide;
dibenz[a, h]anthracene
dibenz[a,h]anthracene
STOT RE 1; H372: C ≥ 1 %
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,2 % ≤ C < 1 %
Carc.
1A; H350: C ≥ 0,001 %
N, N-dimethylethanolamine
N,N-dimethylethanolamine
N, N-diethylethanolamine
N,N-diethylethanolamine
bis[[2,2',2''-nitrilotris-[ethanolato]]-1-N, O]-bis[2-(2-methoxyethoxy)ethoxy]-titanium
bis[[2,2',2''-nitrilotris-[ethanolato]]-1-N,O]-bis[2-(2-methoxyethoxy)ethoxy]-titanium
3-((2-nitro-4-(trifluoromethyl)phenyl)amino)propane-1,2-diol
3-((2-nitro-4-(trifluoromethyl)phenyl)amino)propane-1,2-diol 410-010-0
mono-2-[2-(4-dibenzo[b, f][1,4]thiazepin-11-yl)piperazinium-1-yl]ethoxy)ethanol trans-butenedioate
mono-2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl)piperazinium-1-yl]ethoxy)ethanol trans-butenedioate
1B; H314: C ≥ 10 %
Skin Irrit. 2; H315: 0,5 % ≤ C < 10 % Eye Dam.
Skin Irrit.
2 % ≤ C < 10 % Eye Irrit.
2; H315: 0,5 % ≤ C < 10 % Eye Dam.; H318: 2 % ≤ C < 10 % Eye Irrit.
0,5 % ≤ C < 2 %
2; H319: 0,5 % ≤ C < 2 %
STOT SE; H335: C ≥ 0,5 % Skin Sens.
GHS07
Wng H317 H412
α, α,α-trifluoro-2,6-dinitro-N,N-dipropyl-p-toluidine (containing < 0.5 ppm NPDA);
2,6-dinitro-N,N-dipropyl-4-trifluoromethylaniline (containing < 0.5 ppm NPDA);
2,6-dinitro-N,N-dipropyl-4-trifluoromethylaniline (containing < 0.5 ppm NPDA); N,N-dipropyl-2,6-dinitro-4-trifluoromethylaniline (containing < 0.5 ppm NPDA)
N,N-dipropyl-2,6-dinitro-4-trifluoromethylaniline (containing < 0.5 ppm NPDA)
sodium (1,0—1,95)/lithium (0,05-1) 5-((5-((5-chloro-6-fluoro-pyrimidin-4-yl)amino)-2-sulfonatophenyl)azo)-1,2-dihydro-6-hydroxy-1,4-dimethyl-2-oxo-3-pyridinemethylsulfonate
sodium (1,0-1,95)/lithium (0,05-1) 5-((5-((5-chloro-6-fluoro-pyrimidin-4-yl)amino)-2-sulfonatophenyl)azo)-1,2-dihydro-6-hydroxy-1,4-dimethyl-2-oxo-3-pyridinemethylsulfonate
reaction mass of: 2,4-bis(N'-(4-methylphenyl)-ureido)-toluene;
reaction mass of: 2,4 -bis(N'-(4-methylphenyl)-ureido)-toluene;
2,6-bis(N'-(4-methylphenyl)-ureido)-toluene
2,6 -bis(N'-(4-methylphenyl)-ureido)-toluene
Υγρό 1, H224 εάν το σημείο ανάφλεξης < 23 oC και το αρχικό σημείο βρασμού ≤ 35 oC
1, H224 if flashpoint < 23 oC and initial boiling point ≤ 35 oC Flam.
Υγρό 2, H225 εάν το σημείο ανάφλεξης < 23 oC και το αρχικό σημείο βρασμού > 35 oC
2, H225 if flashpoint < 23 oC and initial boiling point > 35 oC Flam.
Υγρό 1, H224 εάν το αρχικό σημείο βρασμού ≤ 35 oC
1, H224 if initial boiling point ≤ 35 oC Flam.
F+· R12
R12 gas
Η ορθή μετατροπή του F+, R12, αέριο δίδει είτε εύφλ. αέριο 1, H220 είτε εύφλ. αέριο 2, H221.
Gas 1, H220 or Flam. Gas 2, H221.
STOT Rep. 2
STOT RE 2
Τοξικό στην αναπαρ.1Α
1; R60 Repr. 1A
Τοξικό στην αναπαρ.
H360FD
Τοξικό στην αναπαρ.
R61 Repr.
Τοξικό στην αναπαρ.
H360Fd
Τοξικό στην αναπαρ.
R63 Repr.
N· R50
H360Df
Τοξικό στην αναπαρ.
Cat. 2; R61
Τοξικό στην αναπαρ.1Β
R62 Repr.
3 H412 R53
Aquatic Chronic 3
Μετατροπή από τις φράσεις επικινδυνότητας της οδηγίας 67/548/EΟΚ στις συμπληρωματικές απαιτήσεις επισήμανσης του παρόντος κανονισμού
Translation between risk phrases assigned under Directive 67/548/EEC and supplementary labelling requirements under this Regulation Directive 67/548/EEC
Κανονισμός (ΕΚ) αριθ. 1273/2008 της Επιτροπής
Commission Regulation (EC) No 1273/2008
Ο παρών κανονισμός αρχίζει να ισχύει στις 18 Δεκεμβρίου 2008.
This Regulation shall enter into force on 18 December 2008.
Κανονισμος (ΕΚ) αριθ. 1274/2008 της Επιτροπης
Commission Regulation (EC) No 1274/2008
για την τροποποίηση του κανονισμού (ΕΚ) αριθ. 1126/2008 για την υιοθέτηση ορισμένων διεθνών λογιστικών προτύπων σύμφωνα με τον κανονισμό (ΕΚ) αριθ. 1606/2002 του Ευρωπαϊκού Κοινοβουλίου και του Συμβουλίου, όσον αφορά το διεθνές λογιστικό πρότυπο (ΔΛΠ) 1
amending Regulation (EC) No 1126/2008 adopting certain international accounting standards in accordance with Regulation (EC) No 1606/2002 of the European Parliament and of the Council as regards International Accounting Standard (IAS) 1
Στις 6 Σεπτεμβρίου 2007, το Συμβούλιο Διεθνών Λογιστικών Προτύπων (IASB) εξέδωσε το αναθεωρημένο διεθνές λογιστικό πρότυπο (ΔΛΠ) 1 Παρουσίαση των οικονομικών καταστάσεων, εφεξής «αναθεωρημένο ΔΛΠ 1».
On 6 September 2007, the International Accounting Standards Board (IASB) published the revision of International Accounting Standard (IAS) 1 Presentation of Financial Statements, hereinafter ‘revised IAS 1’.
Το αναθεωρημένο ΔΛΠ 1 τροποποιεί ορισμένες από τις απαιτήσεις για την παρουσίαση των οικονομικών καταστάσεων και απαιτεί ορισμένες συμπληρωματικές πληροφορίες· επίσης, τροποποιεί ορισμένα άλλα λογιστικά πρότυπα.
The revised IAS 1 amends some of the requirements for the presentation of the financial statements and requires some additional information in certain circumstances; it also amends some other accounting standards.
Το αναθεωρημένο ΔΛΠ 1 αντικαθιστά το διεθνές λογιστικό πρότυπο (ΔΛΠ) 1 Παρουσίαση των οικονομικών καταστάσεων που αναθεωρήθηκε το 2003, όπως τροποποιήθηκε το 2005.
The revised IAS 1 replaces International Accounting Standard (IAS) 1 Presentation of Financial Statements revised in 2003, as amended in 2005.
Οι διαβουλεύσεις με την ομάδα τεχνικών εμπειρογνωμόνων (TEG) της ευρωπαϊκής συμβουλευτικής ομάδας για θέματα χρηματοοικονομικής πληροφόρησης (EFRAG) επιβεβαιώνουν ότι το αναθεωρημένο ΔΛΠ 1 πληροί τα τεχνικά κριτήρια έγκρισης που ορίζονται στο άρθρο 3 παράγραφος 2 του κανονισμού (ΕΚ) αριθ. 1606/2002.
The consultation with the Technical Expert Group (TEG) of the European Financial Reporting Advisory Group (EFRAG) confirms that the revised IAS 1 meets the technical criteria for adoption set out in Article 3(2) of Regulation (EC) No 1606/2002.
Στο παράρτημα του κανονισμού (ΕΚ) αριθ. 1126/2008, το διεθνές λογιστικό πρότυπο (ΔΛΠ) 1 Παρουσίαση των οικονομικών καταστάσεων (αναθεωρημένο το 2003), όπως τροποποιήθηκε το 2005, αντικαθίσταται από το διεθνές λογιστικό πρότυπο (ΔΛΠ) 1 Παρουσίαση των οικονομικών καταστάσεων (αναθεωρημένο το 2007) όπως ορίζεται στο παράρτημα του παρόντος κανονισμού.
In the Annex to Regulation (EC) No 1126/2008, International Accounting Standard (IAS) 1 Presentation of Financial Statements (revised in 2003), as amended in 2005, is replaced by the International Accounting Standard (IAS) 1 Presentation of Financial Statements (revised in 2007) in the Annex to this Regulation.
Οι εταιρείες εφαρμόζουν το ΔΛΠ 1 (αναθεωρημένο το 2007), όπως ορίζεται στο παράρτημα του παρόντος κανονισμού, το αργότερο από την ημερομηνία έναρξης του πρώτου οικονομικού τους έτους που αρχίζει μετά την 31η Δεκεμβρίου 2008.
Each company shall apply IAS 1 (revised in 2007), as set out in the Annex to this Regulation, at the latest, as from the commencement date of its first financial year starting after 31 December 2008.
ΕΕ L 320 της 29.11.2008, σ. 1
OJ L 320, 29.11.2008, p. 1.
«ΔΛΠ 1 Παρουσίαση των οικονομικών καταστάσεων (αναθεωρημένο το 2007)»
IAS 1 Presentation of Financial Statements (Revised 2007)
ΔΙΕΘΝΕΣ ΛΟΓΙΣΤΙΚΟ ΠΡΟΤΥΠΟ 1
INTERNATIONAL ACCOUNTING STANDARD 1
Παρουσίαση των Οικονομικών Καταστάσεων
Presentation of Financial Statements
1 Το παρόν Πρότυπο περιγράφει τη βάση παρουσίασης των οικονομικών καταστάσεων γενικής χρήσης, ώστε να εξασφαλίζεται συγκρισιμότητα τόσο με τις οικονομικές καταστάσεις των προηγούμενων περιόδων της οικονομικής οντότητας όσο και με τις οικονομικές καταστάσεις άλλων οικονομικών οντοτήτων.
1 This Standard prescribes the basis for presentation of general purpose financial statements to ensure comparability both with the entity’s financial statements of previous periods and with the financial statements of other entities.
Θέτει γενικές απαιτήσεις για την παρουσίαση των οικονομικών καταστάσεων, κατευθυντήριες γραμμές για τη δομή τους και τις ελάχιστες απαιτήσεις για το περιεχόμενό τους.
It sets out overall requirements for the presentation of financial statements, guidelines for their structure and minimum requirements for their content.
2 Οι οικονομικές οντότητες εφαρμόζουν το παρόν Πρότυπο για την κατάρτιση και την παρουσίαση οικονομικών καταστάσεων γενικής χρήσης σύμφωνα με τα Διεθνή Πρότυπα Χρηματοοικονομικής Αναφοράς (Δ.Π.Χ.Α.).
2 An entity shall apply this Standard in preparing and presenting general purpose financial statements in accordance with International Financial Reporting Standards (IFRSs).
3 Άλλα Δ.Π.Χ.Α. θέτουν τις απαιτήσεις αναγνώρισης, επιμέτρησης και γνωστοποίησης συγκεκριμένων συναλλαγών και άλλων γεγονότων.
3 Other IFRSs set out the recognition, measurement and disclosure requirements for specific transactions and other events.
4 Το παρόν Πρότυπο δεν εφαρμόζεται στη δομή και το περιεχόμενο συνοπτικών ενδιάμεσων οικονομικών καταστάσεων που καταρτίζονται σύμφωνα με το Δ.Λ.Π. 34 Ενδιάμεση Χρηματοοικονομική Αναφορά.
4 This Standard does not apply to the structure and content of condensed interim financial statements prepared in accordance with IAS 34 Interim Financial Reporting.